IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`First Named Inventor: Dennis Mark MCDAID|Confirmation No.: 5282
`
`Applicant: XEOLAS PHARMACEUTICALS$|Art Unit: Zo Be Assigned
`LTD.
`
`Application No.: 18/182,797
`
`Examiner: 7o Be Assigned
`
`Filing Date: March 13, 2023
`
`Atty. Docket: 4384.0010005
`
`Title: PEDIATRIC SUSPENSION FORMULATION
`
`First Supplemental Information Disclosure Statement
`
`Mail Stop Amendment
`
`Commissionerfor Patents
`PO Box 1450
`Alexandria, VA 22313-1450
`
`Commissioner:
`
`Listed on the accompanying form equivalent to forms PTO/SB/08a and PTO/SB/08b are
`
`documents that may be considered material to the patentability of this application as defined in 37
`
`C.F.R. § 1.56. The documents are being filed in compliance with the duty of disclosure requirements
`
`of 37 C.F.R. §§ 1.97 and 1.98. The numbering on this First Supplemental Information Disclosure
`
`Statement is a continuation of the numbering in Applicant's Information Disclosure Statementfiled
`
`on September 12, 2023.
`
`Applicant has listed publication dates on the attached form based on information presently
`
`available to the undersigned. However, the listed publication dates should not be construed as an
`
`admission that the information wasactually published on the date indicated.
`
`
`
`-2-
`
`Dennis Mark MCDAID
`Application No.: 18/182,797
`
`Applicant reserves the right to establish the patentability of the claimed invention over any of
`
`the information provided herewith, and/or to prove that this information may notbe priorart, and/or
`
`to prove that this information may not be enabling for the teachings purportedly offered.
`
`This statement should not be construed as a representation that a search has been made,orthat
`
`information more material to the examination of the present patent application does not exist. The
`
`Examineris specifically requested not to rely solely on the material submitted herewith.
`
`Filing under 37 C.F.R. § 1.97(b). This Information Disclosure Statementis being filed before
`
`the mailing date ofa first Office Action on the merits. No statementor fee is required.
`
`A copy of document FP9 is submitted. In accordance with 37 C.F.R. § 1.98(a)(2)(i1), no copy
`
`of document US16 is submitted.
`
`It is respectfully requested that the Examinerinitial and return a copy of the attached IDS
`
`Form, andindicate in the official file wrapper of this patent application that the documents have been
`
`considered. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency,
`
`or credit any overpayment, to our Deposit Account No. 19-0036.
`
`Respectfully submitted,
`
`STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
`
`/Matthew S. Bodenstein/
`
`Matthew S. Bodenstein
`Attorney for Applicant
`Registration No. 58,885
`
`222710471
`
`Atty. Dkt. No. 4384.0010005
`
`April 29, 2024
`Date:
`1101 K Street, NW, 10" Floor
`Washington, D.C. 20005
`Main: 202-371-2600
`Direct: 202-772-8787
`
`
Still Working On It
This document is taking longer than usual to download. This can
happen if we need to contact the court directly to obtain the
document and their servers are running slowly.
Give it another minute or two to complete, and then try the
refresh button.
